Indication

Gastric hypersecretion with systemic mastocytosis

Gastric hypersecretion with systemic mastocytosis is a gastrointestinal complication of a rare hematologic neoplasm marked by the abnormal accumulation and activation of clonal mast cells within extracutaneous tissues. Read more about Gastric hypersecretion with systemic mastocytosis

502 drugs 204 manufacturers

Advertisement

Drugs that treat it

Common Gastric hypersecretion with systemic mastocytosis therapies.

Showing 10–18 of 502 drugs

OMEPRAZOLE

PEPTIC ULCER AGENTS·ZOLLINGER-ELLISON SYNDROME·+10
Major Pharamceuticals

OMEPRAZOLE

PEPTIC ULCER AGENTS·ZOLLINGER-ELLISON SYNDROME·+10
TOPCO
Filter & compare in the drug finder →Opens the drug finder with Gastric hypersecretion with systemic mastocytosis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Gastric hypersecretion with systemic mastocytosis.

Gastric hypersecretion with systemic mastocytosis is a gastrointestinal complication of a rare hematologic neoplasm marked by the abnormal accumulation and activation of clonal mast cells within extracutaneous tissues.

This hypersecretory state occurs when systemic degranulation of mast cells releases excessive circulating histamine, which binds to histamine H2 receptors on gastric parietal cells to overstimulate hydrochloric acid production.

Clinically, affected individuals present with marked increases in basal acid output that predispose them to refractory peptic ulcer disease, erosive gastritis, duodenitis, acid-induced diarrhea, and upper gastrointestinal bleeding.

Personalize your experience

Follow Gastric hypersecretion with systemic mastocytosis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it